In reply 2

Affiliations

¹ Department of Respiratory Medicine, Auckland District Health Board, Auckland, Centre for International Health, University of Otago, Dunedin.
² Department of Respiratory Medicine, Auckland District Health Board, Auckland.
³ Department of Chemical Pathology, LabPlus Laboratories, Auckland.
⁴ Research Office, Auckland District Health Board.

Comment

M J Maze et al. Int J Tuberc Lung Dis. 2016 Dec.

. 2016 Dec;20(12):1696-1697.

doi: 10.5588/ijtld.16.0550-3.

¹ Department of Respiratory Medicine, Auckland District Health Board, Auckland, Centre for International Health, University of Otago, Dunedin.
² Department of Respiratory Medicine, Auckland District Health Board, Auckland.
³ Department of Chemical Pathology, LabPlus Laboratories, Auckland.
⁴ Research Office, Auckland District Health Board.

No abstract available

Comment on

Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Maze MJ, Paynter J, Chiu W, Hu R, Nisbet M, Lewis C. Maze MJ, et al. Int J Tuberc Lung Dis. 2016 Jul;20(7):955-60. doi: 10.5588/ijtld.15.0792. Int J Tuberc Lung Dis. 2016. PMID: 27287650
Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.
Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC. Sturkenboom MG, et al. Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. doi: 10.5588/ijtld.16.0550. Int J Tuberc Lung Dis. 2016. PMID: 27931348 No abstract available.